Table 1.
Patients’ demographics, tumor characteristic, prognostic factor, and clinical outcomes
| Authors | Year of publication | Data | Number of patients | Histologic subtype | Adjuvant therapy | Prognostic factors | Clinical outcomes |
|---|---|---|---|---|---|---|---|
| Adem et al. [1] | 2004 | Single institution study | 25 | Fibrosarcoma, angiosarcoma, pleomorphic sarcoma > myxofibrosarcoma > leiomyosarcoma > hemangiopericytoma, osteosarcoma, excluding radiation-induced sarcoma and phyllodes tumor | 1 adjuvant chemotherapy; 4 adjuvant radiotherapy | Tumor size > 5 cm | Overall survival 66% Sarcoma-specific survival 70% at 5 years |
| Bousquet et al. [3] | 2007 | Multicenter study | 103 | Angiosarcoma (including radiation-induced sarcoma) >> malignant histiocytofibroma > fibrosarcoma > liposarcoma > leiomyosarcoma > osteogenic sarcoma, excluding phyllodes tumor | 11 neoadjuvant chemotherapy; 19 adjuvant chemotherapy; 50 adjuvant radiotherapy | Residual tumor after treatment, cellular pleomorphism, angiosarcoma | Overall survival 44% at 5 years |
| Fields et al. [14] | 2008 | Single institution study | 13 | Leiomyosarcoma = malignant fibrous histiocytoma = fibrosarcoma > carcinosarcoma = angiosarcoma = epithelioid cell sarcoma = rhabdomyosarcoma, excluding radiation-induced sarcoma and phyllodes tumor | 5 adjuvant chemotherapy; 9 adjuvant radiotherapy | Tumor size > 5 cm | Overall survival 67% at 5 years |
| Pencavel et al. [4] | 2011 | Single institution study | 63 | Angiosarcoma (including radiation-induced sarcoma) > phyllodes tumor > dermatofibrosarcoma protuberans > Leiomyosarcoma > fibrosarcoma = pleomorphic > malignant fibrous histiocytoma = synovial | No adjuvant chemotherapy; 24 neoadjuvant radiotherapy | Radiation-induced sarcoma | Sarcoma-specific survival 93% at 2 years, 78% at 5 years |
| Toesca et al. [2] | 2012 | Single institution study | 203 | Angiosarcoma (including radiation-induced sarcoma) >> stromal sarcoma excluding phyllodes and dermatofibrosarcoma | 5 adjuvant chemotherapy; 6 adjuvant radiotherapy | Secondary sarcoma (radiation-induced sarcoma, chronic lymphedema) | Sarcoma-specific survival 56.6% at 5 years |
> greater than, >> much greater than, = equals